Tirzepatide is a synthetic peptide sequence containing 39 amino acids, structurally engineered as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In biochemical assays, it is utilized to map downstream insulinotropic pathways, pancreatic beta-cell interaction, and receptor-binding kinetics in laboratory models.